Efficacy of Bacillus Calmette–Guérin (BCG) Vaccination in Reducing the Incidence and Severity of COVID-19 in High-Risk Population (BRIC): a Phase III, Multi-centre, Quadruple-Blind Randomised Control Trial

Efficacy of Bacillus Calmette–Guérin (BCG) Vaccination in Reducing the Incidence and Severity of COVID-19 in High-Risk Population (BRIC): a Phase III, Multi-centre, Quadruple-Blind Randomised Control Trial

Plain Language Summary The Bacillus Calmette–Guérin (BCG) vaccine has been studied previously in several settings, including reducing childhood mortalities due to viral infections and induction of trained immunity and reducing upper respiratory tract infections and pneumonia in older adults. This mu...

Full description

Bibliographic Details
Main Authors: Sanjeev Sinha, Anuj Ajayababu, Himanshu Thukral, Sushil Gupta, Subhasish Kamal Guha, Ayan Basu, Gaurav Gupta, Prashant Thakur, Raghavendra Lingaiah, Bimal Kumar Das, Urvashi B. Singh, Ravinder Singh, Rajiv Narang, Dipankar Bhowmik, Naveet Wig, Dolan Champa Modak, Bhaswati Bandyopadhyay, Banya Chakrabarty, Aditya Kapoor, Satyendra Tewari, Narayan Prasad, Zia Hashim, Alok Nath, Niraj Kumari, Ravinder Goswami, Shivam Pandey, Ravindra Mohan Pandey
Format: Article
Language:English
Published: Adis, Springer Healthcare 2022-10-01
Series:Infectious Diseases and Therapy
Subjects:
BCG vaccination
Incidence of COVID-19
Severe COVID-19
Symptomatic COVID-19
Vaccine efficacy
Online Access:https://doi.org/10.1007/s40121-022-00703-y

Internet

https://doi.org/10.1007/s40121-022-00703-y

Similar Items